Reproductive health of parents
Keywords:reproductive health, myo-inositol, folic acid, congenital malformations
The reproductive health of parents is the onset and further physiological course of pregnancy, childbirth and health of the unborn child. Saving of reproductive health can be considered as protecting the family from factors with “reproductive toxicity”, that is lead to morphological and functional changes in the germ cells, organs and systems of embryo. The risk of infertility and miscarriage is significantly higher in couples where a man and a woman have balanced chromosomal rearrangements or gene polymorphisms. In the future, we will be able to block genotoxic lesions of the genome at the gene level.
Research and development of experience on this issue continues. Now there are already some promising methods, which include nutritional support at the stage of pregnancy planning using folic acid and myo-inositol. New guidelines have been developed for folic acid, metafolin, MTHFR gene variants, and others. Neural tube defects are more common in people with MTHFR 677 CT and TT genotypes in countries where food folate fortification is not used, so they did not get enough of it. Women who are planning a pregnancy and have previously children with malformations are recommended to intake folic acid 4000 µg daily, starting 1 month before pregnancy and during the first 3 months of gestation.
However, getting ready for pregnancy is much more than 3 or 12 months before conception. Preparing for pregnancy is a healthy lifestyle for parents from the moment they are conceived to their reproductive years. Saving of reproductive health is protection against genotoxic damage. Genotoxic substances act in different periods of life with different intensity of strength and time, therefore, the program for maintaining reproductive health should begin from the moment of conception of future parents. At the same time, the reproductive health saving program applies to both women and men.
- Shaeffer, C., Peters, P., Miller, R.K. Drugs during pregnancy and lactation. Treatment options and risk assessment. UK-USA (2007): 875 p.
- Macklon, N., Geraedts, J., Fauser, B. “Conception to ongoing pregnancy: the “black box” of early pregnancy loss.” Hum Reproduc Update 8.4 (2002): 333–43.
- Collins, J., Diedrich, K., Franks, S., et al. “Genetic aspects of female reproduction.” Hum Reprod Update 14 (2008): 293–307.
- Yurov, I.Y., Vorsaneova, S.G., Silvanovich, A.P., et al. “Variations in the genome of a somatic cell in norm and in hereditary pathology during ontogenesis.” Med genetics 6 (2012): 11–9.
- Peltonen, L., McKusick, V. “Dissecting Human Disease in the Post-Genomic Era.” Science 29 (2001): 1224–9.
- Durnev, А.D., Zhanataev, A.K., Shreder, O.V., Seredenina, V.S. “Genotoxic events and diseases.” Molecular medicine 3 (2013): 3–19.
- Mаkkonki, A. The human genome. M., Technosphere, 2008. 288 p.
- Morrison, J.C., Elliott, J., Knuppel, R.A., et al. “Current issues and perspectives in prenatal nutrition.” Research and Reports in Neonatology 1 (2011): 25–38.
- Wilson, R.D., Audibert, F., Brock, J.A., et al. “Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies.” J Obstet Gynaecol Can 37.6 (2015): 534–52.
- Czeizel, A.E., Dudás, I., Vereczkey, A., Bánhidy, F. “Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects.” Nutrients 5.11 (2013): 4760–75. DOI: 10.3390/nu5114760
- Mert, I., Oruc, A.S., Yuksel, S. “Role of oxidative stress in preeclampsia and intrauterine growth restriction.” J Obstet Gynaecol Res 38.4 (2012): 658–64. DOI: 10.1111/j.1447-0756.2011.01771.x
- MTHFR Gene, Folic Acid, and Preventing Neural Tube Defects. Available from: [https://www.cdc.gov/ncbddd/folicacid/mthfr-gene-and-folic-acid.html].
- Tsang, B.L., Devine, O.J., Cordero, A.M., et al. “Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies.” Am J Clin Nutr 101.6 (2015): 1286–94.
- Centers for Disease Control and Prevention. Folic Acid. Available from: [https://www.cdc.gov/ncbddd/folicacid/about.html#folate-and-folic-acid].
- Sweeney, M.R., McPartlin, J., Weir, D.G., et al. “Postprandial serum folic acid response to multiple doses of folic acid in fortified bread.” Br J Nutr 95 (2006): 145–51.
- Yang, Q., Bailey, L., Clarke, R., et al. “Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults.” Am J Clin Nutr 95.5 (2012): 1245–53.
- Crider, K.S., Devine, O., Qi, Y.P., et al. “Systematic review and Bayesian meta-analysis of the dose-response relationship between folic acid intake and changes in blood folate concentrations.” Nutrients 11.1 (2019): E71.
- Gromova, O.A., Torshin, I.Y., Tetruashvili, N.K. “The role of myo-inositol in maintaining a woman's reproductive health. Improving the efficiency of in vitro fertilization technologies.” RMM Mother and Child 1 (2018): 88–95. DOI: 10.32364/2618-8430-2018-1-1-88-95
- Ge, W., Jiao, Y., Chang, L. “The association between MTHFR gene polymorphisms (C677T, A1298C) and oral squamous cell carcinoma: a systematic review and meta-analysis.” PloS One 13.8 (2018): e0202959.
- ElGendy, K., Malcomson, F.C., Lara, J.G., et al. “Effects of dietary interventions on DNA methylation in adult humans: systematic review and meta-analysis.” BrJ Nutr 120.9 (2018): 961–76.
- Luo, Z., Lu, Z., Muhammad, I., et al. “Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis.” Lipids Health Dis 17.1 (2018): 191.
- Zhang, Y., He, X., Xiong, X., et al. “The association between maternal methylenetetrahydrofolate reductase C677T and A1298C polymorphism and birth defects and adverse pregnancy outcomes.” Prenat Diagn 39.1 (2019): 3–9.
- Huo, Y., Li, J., Qin, X., et al. “Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.” JAMA 313.13 (2015): 1325–35.
- Stampfer, M., Willett, W. “Folate supplements for stroke prevention: targeted trial trumps the rest.” JAMA 313.13 (2015): 1321–2.
- Li, Y., Huang, T., Zheng, Y., et al. “Folic acid supplementation and the risk of cardiovascular diseases: a meta-analysis of randomized controlled trials.” J Am Heart Assoc 5.8 (2016): e003768.
- Gamble, M.V., Liu, X., Slavkovich, V., et al. “Folic acid supplementation lowers blood arsenic.” Am J Clin Nutr 86.4 (2007): 1202–9.
- Yan, L., Zhao, L., Long, Y., et al. “Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects in offsprings: evidence from 25 case-control studies.” PloS One 7.10 (2012): e41689.
- Crider, K.S., Zhu, J.H., Hao, L., et al. “MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation.” Am J Clin Nutr 93.6 (2011): 1365–72.
- Zhang, T., Lou, J., Zhong, R., et al. “Genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature.” PloS One 8.4 (2013): e59570.
- Yadav, U., Kumar, P., Yadav, S.K., et al. “Polymorphisms in folate metabolism genes as maternal risk factor for neural tube defects: an updated meta-analysis.” Metab Brain Dis 30.1 (2015): 7–24.
- Centers for Disease Control and Prevention. Consuming enough folate helps prevent neural tube defects. Available from: [https://www.cdc.gov/ncbddd/folicacid/consuming-enough-folate-helps-prevent-neural-tube-defects.html#genotype].
- Berry, R.J., Li, Z., Erickson, J.D, et al. “Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention.” N Engl J Med 341.20 (1999): 1485–90.
- Crider, K.S., Devine, О., Hao, L., et al. “Population red blood cell folate concentrations for prevention of neural tube defects: bayesian model.” BMJ 349 (2014): g4554.
- Venn, B.J., Green, T.J., Moser, R., et al. “Increases in blood folate indices are similar in women of childbearing age supplemented with [6S]-5-methyltetrahydrofolate and folic acid.” J Nutr 132 (2002): 3353–5.
- Navarrete-Muñoz, E.M., Valera-Gran, D., Garcia-De-La-Hera, M., et al. “High doses of folic acid in the periconceptional period and risk of low weight for gestational age at birth in a population based cohort study.” Eur J Nutr 58 (2017): 241–51.
- Alves-Santos, N.H., Guedes-Cocate, P., Benaim, C., et al. “Prepegnancy dietary patterns and their association with perinatal outcomes: а prospective cohort study.” J Acad Nutri Diet 119 (2019): 1439–51.
- Bulloch, R.E., Wall, C.R., McCowan, L.M.E., et al. “The Effect of interactions between folic acid supplementation and one carbon metabolism gene variants on small-for-gestational-age births in the Screening for Pregnancy Endpoints (SCOPE) cohort study.” Nutrients 12 (2020): 1677.
- World Health Organization. Recommendations on Antenatal Care for a Positive Pregnancy Experience; WHO: Geneva, Switzerland, 2016.
- Naninck, E.F.G., Stijger, P.C., Brouwer-Brolsma, E.M. “The importance of maternal folate status for brain development and function of offspring.” Adv Nutr 10 (2019): 502–19.
- Shin, J.-A., Kim, Y.-J., Park, H., et al. “Localization of folate metabolic enzymes, methionine synthase and 5,10-methylenetetrahydrofolate reductase in human placenta.” Gynecol Obstet Investig 78 (2014): 259–65.
- Kumar, A., Moulik, N.R., Agrawal, S. “Folic acid, one-carbon metabolism & childhood cancer.” Indian J Med Res 146 (2017): 163–74.
- Field, M.S., Stover, P.J. “Safety of folic acid.” Ann NY Acad Sci 1414 (2018): 59–71.
- Smallwood, T., Allayee, H., Bennett, B.J. “Choline metabolites: Gene by diet interactions.” Curr Opin Lipidol 27 (2016): 33–9.
- Wu, H., Zhu, P., Geng, X., et al. “Genetic polymorphism of MTHFR(677)C>T whit preterm birth and low birth weight susceptibility: A meta-analysis.” Arch Gynecol Obstet 295 (2017): 1105–18.
- Chen, H., Yang, X., Lu, M. “Methylenetetrahydrofolate reductase gene polymorphisms and recurrent pregnancy loss in China: A systematic review and meta-analysis.” Arch Gynecol Obstet 293 (2016): 283–90.
- Golja, M.V., Šmid, A., Kuželički, N.K., et al. “Folate insufficiency due to MTHFR deficiency is bypassed by 5-methyltetrahydrofolate.” J Clin Med 9 (2020): 2836.
- Niederberger, K., Dahms, I., Broschard, T., et al. “Safety evaluation of calcium L-methylfolate.” Toxicol Rep 6 (2019): 1018–30.
- Moreau, J., Kesteven, S., Martin, E., et al. “Gene-environment interaction impacts on heart development and embryo survival.” Development 146.4 (2019): dev172957.
- Kalayinia, S., Maleki, M., Mahdavi, M., Mahdieh, N. “A novel de novo dominant mutation of NOTCH1 gene in an Iranian family with non-syndromic congenital heart disease.” J Clin Lab Anal 34.4 (2020): e23147.
- Kalayinia, S., Maleki, M., Rokni-Zadeh, H., et al. “GATA4 screening in Iranian patients of various ethnicities affected with congenital heart disease: Co-occurrence of a novel de novo translocation (5;7) and a likely pathogenic heterozygous GATA4 mutation in a family with autosomal dominant congenital heart disease.” J Clin Lab Anal 33.7 (2019): 23.
How to Cite
Copyright (c) 2021 О.М. Юзько
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.